Assessing the Proposed Changes to the US FDA's 510(k) Programme
This article was originally published in SRA
Executive Summary
Karen M Becker says that modifications to the Food and Drug Administration's pre-market notification process may lead to the introduction of unnecessary regulatory burdens.
You may also be interested in...
Assessing the Proposed Changes to the US FDA's 510(k) Programme
Karen M Becker says that modifications to the Food and Drug Administration's pre-market notification process may lead to the introduction of unnecessary regulatory burdens.